Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 11/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.52 |
| ▸ | CDK2 | P24941 | 8/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 4/20 | 0.43 |
| ▸ | BCR | P11274 | 4/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196103 | 0.91 | CDK5 (0.53) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5193482 | 0.82 | CDK5 (0.60) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5630231 | 0.80 | CDK5 (0.61) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5195354 | 0.79 | CDK1 (0.61) | CDK2CDK1 | |
| SCHEMBL5195357 | 0.79 | CDK1 (0.61) | CDK2CDK1 | |
| SCHEMBL5193365 | 0.79 | CDK5 (0.78) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL5628160 | 0.79 | CDK1 (0.60) | CDK2CDK1 | |
| Hydrochloric Acid SCHEMBL5628157 | 0.79 | CDK1 (0.60) | CDK2CDK1 | |
| SCHEMBL6947470 | 0.76 | FLT3 (0.52) | CDK2NPC1ABL1BCR | |
| SCHEMBL5193529 | 0.73 | CDK5 (0.62) | CDK5CDK5R1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183256-B1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| EP-1183256-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071543-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | CDK5 15/4885CDK5R1 51/4885CCNA2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.